Twin Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.23M Buy
19,426
+447
+2% +$99.2K 0.54% 37
2025
Q4
$4.34M Sell
18,979
-4,393
-19% -$1M 0.54% 37
2025
Q3
$5.41M Sell
23,372
-17,033
-42% -$3.47M 0.68% 24
2025
Q2
$7.5M Buy
40,405
+1,359
+3% +$253K 0.8% 22
2025
Q1
$8.18M Sell
39,046
-806
-2% -$157K 0.95% 17
2024
Q4
$7.08M Buy
39,852
+3,214
+9% +$591K 0.78% 20
2024
Q3
$7.24M Sell
36,638
-402
-1% -$75K 0.82% 17
2024
Q2
$6.35M Buy
37,040
+509
+1% +$84.3K 0.75% 21
2024
Q1
$6.65M Sell
36,531
-1,650
-4% -$284K 0.82% 18
2023
Q4
$5.92M Buy
38,181
+1,417
+4% +$207K 0.78% 21
2023
Q3
$5.48M Buy
36,764
+11,052
+43% +$1.62M 0.79% 20
2023
Q2
$3.46M Buy
25,712
+3,858
+18% +$566K 0.45% 56
2023
Q1
$3.48M Sell
21,854
-3,972
-15% -$607K 0.48% 54
2022
Q4
$4.17M Buy
25,826
+357
+1% +$54.7K 0.54% 46
2022
Q3
$3.42M Sell
25,469
-25
-0.1% -$3.59K 0.46% 57
2022
Q2
$3.9M Buy
25,494
+100
+0.4% +$15.3K 0.5% 52
2022
Q1
$4.12M Sell
25,394
-80
-0.3% -$11.6K 0.44% 64
2021
Q4
$3.45M Sell
25,474
-2,270
-8% -$268K 0.35% 95
2021
Q3
$2.99M Sell
27,744
-4,700
-14% -$537K 0.31% 107
2021
Q2
$3.65M Buy
32,444
+929
+3% +$105K 0.34% 98
2021
Q1
$3.41M Sell
31,515
-6,830
-18% -$731K 0.34% 91
2020
Q4
$4.11M Sell
38,345
-12,872
-25% -$1.24M 0.37% 81
2020
Q3
$4.49M Sell
51,217
-2,771
-5% -$261K 0.41% 73
2020
Q2
$5.3M Buy
53,988
+11,439
+27% +$1.01M 0.51% 50
2020
Q1
$3.24M Sell
42,549
-670
-2% -$57.1K 0.35% 88
2019
Q4
$3.83M Sell
43,219
-20,470
-32% -$1.7M 0.32% 103
2019
Q3
$4.82M Sell
63,689
-6,206
-9% -$425K 0.35% 99
2019
Q2
$5.08M Sell
69,895
-44,825
-39% -$3.52M 0.35% 104
2019
Q1
$9.24M Buy
114,720
+160
+0.1% +$13.1K 0.46% 65
2018
Q4
$10.6M Sell
114,560
-5,201
-4% -$457K 0.6% 44
2018
Q3
$11.3M Buy
119,761
+7,889
+7% +$748K 0.52% 54
2018
Q2
$10.4M Buy
111,872
+19,222
+21% +$1.88M 0.52% 53
2018
Q1
$8.77M Buy
+92,650
New +$10.2M 0.45% 66
2017
Q3
Sell
-13,168
Closed -$955K 326
2017
Q2
$955K Buy
+13,168
New +$885K 0.06% 277
2016
Q4
Sell
-4,990
Closed -$315K 325
2016
Q3
$315K Sell
4,990
-2,000
-29% -$129K 0.02% 322
2016
Q2
$433K Sell
6,990
-500
-7% -$30.5K 0.03% 329
2016
Q1
$428K Hold
7,490
0.03% 256
2015
Q4
$444K Sell
7,490
-48,000
-87% -$2.76M 0.04% 251
2015
Q3
$3.02M Sell
55,490
-50,030
-47% -$3.26M 0.29% 108
2015
Q2
$7.09M Buy
105,520
+17,130
+19% +$1.12M 0.64% 42
2015
Q1
$5.17M Buy
88,390
+11,420
+15% +$690K 0.45% 66
2014
Q4
$5.04M Buy
76,970
+1,520
+2% +$95.8K 0.48% 60
2014
Q3
$4.36M Sell
75,450
-6,270
-8% -$348K 0.44% 68
2014
Q2
$4.61M Buy
81,720
+37,670
+86% +$1.98M 0.46% 59
2014
Q1
$2.26M Sell
44,050
-15,150
-26% -$766K 0.24% 137
2013
Q4
$3.13M Sell
59,200
-28,420
-32% -$1.4M 0.33% 96
2013
Q3
$3.92M Sell
87,620
-7,580
-8% -$336K 0.42% 63
2013
Q2
$3.94M Buy
+95,200
New +$4.16M 0.42% 56

Other funds holding ABBV

Twin Capital Management's ABBV Position: Q1 2026 in Review

Twin Capital Management increased its AbbVie (ABBV) stake by 2.4% in Q1 2026, buying an estimated $99.2K and bringing the position to 19,426 shares worth $4.23M. The position accounts for 0.54% of the portfolio, ranked #37.

Twin Capital Management first reported a position in ABBV in Q2 2013 and has held it in 48 quarters since. The position peaked at $11.3M in Q3 2018. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Twin Capital Management held 19,426 shares of AbbVie worth $4.23M as of Q1 2026.
  • Twin Capital Management bought 447 AbbVie shares in Q1 2026, an estimated $99.2K.
  • AbbVie made up 0.54% of Twin Capital Management's portfolio in Q1 2026, its #37 holding.
  • Twin Capital Management first reported a position in AbbVie in Q2 2013 and has held it in 48 quarters since.
  • Twin Capital Management's AbbVie position peaked at $11.3M in Q3 2018.
  • 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Twin Capital Management's 13F filing for Q1 2026, filed 5 May 2026.